What are the long-term risks of using Prolia?

What Long-Term Risks Have Been Associated with Prolia Use?

Prolia, also known as denosumab, is a medication used to treat osteoporosis and bone metastases in cancer patients [1]. While effective, long-term use has been linked to various risks. One major concern is increased risk of skin infections when co-administered with TNF inhibitors, a class of medications used to treat autoimmune diseases [2].

What is the Risk of Jaw Problems with Long-Term Prolia Use?

Long-term Prolia use has been associated with jaw problems, including osteonecrosis of the jaw, a condition characterized by death of jaw bone tissue [3]. This risk is more pronounced in patients with a history of dental surgery or other jaw conditions [4].

Are There Risks to Wound Healing with Prolia?

Yes, Prolia can impair wound healing, particularly at the site of surgery or injury [5]. Healthcare providers closely monitor patients for signs of delayed healing when administering Prolia.

What are the Long-Term Effects of Prolia on Bone Density?

Studies suggest that long-term Prolia use may lead to bone mineral density (BMD) loss in teeth, potentially increasing the risk of dental complications [6]. Conversely, Prolia has been shown to preserve BMD in the spine and hip, reducing the risk of osteoporotic fractures in some patients [7].

Can Prolia Increase the Risk of Certain Cancers?

There have been reports of an increased risk of certain cancers, including thyroid cancer, in patients using Prolia [8]. However, more research is needed to fully understand the relationship between Prolia and cancer risk.

It's essential to consult with a healthcare provider to weigh the benefits and risks of using Prolia, particularly in the context of long-term treatment.

Sources:

[1] Amgen. (n.d.). Prolia (Denosumab).

[2] U.S. National Institutes of Health. (n.d.). Denosumab.

[3] FDA. (2020). Prolia (Denosumab).

[4] National Cancer Institute. (2020). Denosumab and osteonecrosis of the jaw.

[5] Amgen. (n.d.). Prolia (Denosumab) Prescribing Information.

[6] FDA. (2020). Prolia (Denosumab).

[7] U.S. National Institutes of Health. (n.d.). Denosumab.

[8] National Cancer Institute. (2020). Denosumab and cancer risk.